ProfileGDS5678 / 1439497_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 66% 66% 75% 70% 62% 66% 69% 66% 67% 66% 66% 66% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5408458
GSM967853U87-EV human glioblastoma xenograft - Control 23.9872766
GSM967854U87-EV human glioblastoma xenograft - Control 34.0181966
GSM967855U87-EV human glioblastoma xenograft - Control 45.0854975
GSM967856U87-EV human glioblastoma xenograft - Control 54.3084170
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7782562
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0146166
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2808969
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0298566
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0643167
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0077866
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0105866
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0200866
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8242564